CD274 and neoplasm: Another study showed that targeting IL-6 increased the expression of PD-L1 on the melanoma cells and attracted the expression of T-cell inflammatory cytokines in the tumor microenvironment and enhanced the activity of anti-PD-L1 therapy [59].